During the last session, Compugen Ltd (NASDAQ:CGEN)’s traded shares were 0.41 million, with the beta value of the company hitting 2.97. At the end of the trading day, the stock’s price was $2.22, reflecting an intraday gain of 1.37% or $0.03. The 52-week high for the CGEN share is $3.03, that puts it down -36.49 from that peak though still a striking 39.19% gain since the share price plummeted to a 52-week low of $1.35. The company’s market capitalization is $198.77M, and the average intraday trading volume over the past 10 days was 0.82 million shares, and the average trade volume was 711.03K shares over the past three months.
Compugen Ltd (CGEN) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. CGEN has a Sell rating from 0 analyst(s) out of 3 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 3 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.08.
Compugen Ltd (NASDAQ:CGEN) trade information
Compugen Ltd (CGEN) registered a 1.37% upside in the last session and has traded in the red over the past 5 sessions. The stock spiked 1.37% in intraday trading to $2.22, hitting a weekly high. The stock’s 5-day price performance is -13.62%, and it has moved by 10.45% in 30 days. Based on these gigs, the overall price performance for the year is 1.83%. The short interest in Compugen Ltd (NASDAQ:CGEN) is 1.41 million shares and it means that shorts have 1.35 day(s) to cover.
The consensus price target of analysts on Wall Street is $4, which implies an increase of 44.5% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $4 and $4 respectively. As a result, CGEN is trading at a discount of -80.18% off the target high and -80.18% off the low.
Compugen Ltd (CGEN) estimates and forecasts
In the rating firms’ projections, revenue will increase 31.12% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 17.47M as predicted by 3 analyst(s). Meanwhile, a consensus of 1 analyst(s) estimates revenue growth to 5M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 33.46M and 2.56M respectively. In this case, analysts expect current quarter sales to shrink by -47.78% and then jump by 95.39% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 12.14%. While earnings are projected to return 66.67% in 2025, the next five years will return -3.82% per annum.
CGEN Dividends
Compugen Ltd is due to release its next quarterly earnings in March. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
The next largest institutional holding, with 1.31 million shares, is of TAYLOR FRIGON CAPITAL MANAGEMENT LLC’s that is approximately 1.4681% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $2.21 million.
Also, the Mutual Funds coming in first place with the largest holdings of Compugen Ltd (CGEN) shares are Delaware Group Equity Fds IV-Delaware Healthcare Fund and PFS Funds-Taylor Frigon Core Growth Fund . Data provided on Sep 30, 2024 indicates that Delaware Group Equity Fds IV-Delaware Healthcare Fund owns about 1.02 shares. This amounts to just over 1.14 percent of the company’s overall shares, with a $2.26 million market value. The same data shows that the other fund manager holds slightly less at 242.97, or about 0.27% of the stock, which is worth about $0.54 million.
